Theralase Technologies (CVE:TLT) Trading Down 3%

Theralase Technologies Inc. (CVE:TLT)’s stock price dropped 3% during trading on Friday . The company traded as low as C$0.16 and last traded at C$0.16. Approximately 65,575 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 128,920 shares. The stock had previously closed at C$0.17.

Theralase Technologies Trading Down 3.0 %

The stock has a market capitalization of C$37.62 million, a P/E ratio of -8.00 and a beta of 1.66. The firm’s 50 day simple moving average is C$0.19 and its two-hundred day simple moving average is C$0.19. The company has a quick ratio of 3.40, a current ratio of 1.22 and a debt-to-equity ratio of 25.07.

Theralase Technologies (CVE:TLT) last released its quarterly earnings data on Wednesday, March 27th. The company reported C($0.01) EPS for the quarter. The firm had revenue of C$0.36 million during the quarter. As a group, analysts forecast that Theralase Technologies Inc. will post -0.05 earnings per share for the current fiscal year.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.